181 related articles for article (PubMed ID: 38057816)
1. RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells.
Chen Y; He Z; Yang S; Chen C; Xiong W; He Y; Liu S
J Transl Med; 2023 Dec; 21(1):886. PubMed ID: 38057816
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RUNX1 promotes cisplatin-induced apoptosis in ovarian cancer cells.
Xiao L; Peng Z; Zhu A; Xue R; Lu R; Mi J; Xi S; Chen W; Jiang S
Biochem Pharmacol; 2020 Oct; 180():114116. PubMed ID: 32579960
[TBL] [Abstract][Full Text] [Related]
3. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
4. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
5. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
Aptecar L; Puech C; Lopez-Crapez E; Peter M; Coopman P; D'Hondt V; Freiss G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895093
[TBL] [Abstract][Full Text] [Related]
6. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.
Keita M; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Trinh XB; Bachvarov D
Cell Cycle; 2013 Mar; 12(6):972-86. PubMed ID: 23442798
[TBL] [Abstract][Full Text] [Related]
7. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
[TBL] [Abstract][Full Text] [Related]
8. High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Wang H; Ye F; Zhou C; Cheng Q; Chen H
PLoS One; 2021; 16(2):e0245733. PubMed ID: 33635867
[TBL] [Abstract][Full Text] [Related]
9. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
10. ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway.
Luo M; Zhou L; Zhan SJ; Cheng LJ; Li RN; Wang H; Liu B; Linghu H
Biochem Biophys Res Commun; 2019 May; 513(2):528-533. PubMed ID: 30979497
[TBL] [Abstract][Full Text] [Related]
11. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
12. RUNX1-Regulated Signaling Pathways in Ovarian Cancer.
Chen Y; He Y; Liu S
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760803
[TBL] [Abstract][Full Text] [Related]
13. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
15. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
Luo X; Cao J; Zhang C; Huang H; Liu J
Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
17. Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance.
Dhadve AC; Hari K; Rekhi B; Jolly MK; De A; Ray P
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165754. PubMed ID: 32142859
[TBL] [Abstract][Full Text] [Related]
18. Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells.
Ma Y; Liu L; Wei Z; Zhu M; Huang L; Wang S; Yi X; Ying F; Zhao S; Cai J; Wang Z; Sun S
Mol Carcinog; 2023 Apr; 62(4):479-492. PubMed ID: 36621979
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
20. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
